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MinireviewMolecular Mechanisms
of Muscle Atrophy
which are responsible for substrate specificity of ubiqui-
tin conjugation. Furthermore, the observation that ge-
netic deletion of either atrogin-1/MAFbx or MuRF1 re-
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sults in a partial protection against muscle wastingOttawa
demonstrates that dissection of the molecular regula-Ontario K1H 8L6
tion of these two proteins is of great significance withCanada
regard to their resulting effects on muscle atrophy (Bo-
dine et al., 2001a).
The presence of distinct atrophic processes de-Skeletal muscle atrophy has extreme adverse conse-
scribed above raises questions regarding whether mus-quences.Molecularmechanisms thatmediate the pro-
cle atrophy (the result of increased protein catabolism)cess of atrophy are not well defined. Recent studies
as the converse process of muscle hypertrophy (re-have focusedon diversemolecular cascades that con-
sulting from increased protein anabolism) occurs viatrol the activation of ubiquitin ligases, indicating that
entirely independent processes or if these two mecha-the involvement of the ubiquitin proteasome may be
nisms are in some way coregulated. A significant ad-common to a range of atrophic stimuli.
vance in our understanding of the molecular control of
muscle has arisen from the recent work of two groupsSkeletal muscle atrophy can be defined as a wasting or
that focuses on the role of insulin growth factor (IGF)decrease in muscle mass owing to injury, lack of use,
signaling cascades that converge to control the balanceor disease. As is clear from this definition, the etiology
between hypertrophy and atrophy. When released, IGFof atrophy can bediverse.Within the general population,
binds to the IGF receptor, resulting in the activation ofatrophy most commonly results from disuse, which can
a number of signaling cascades. One involves stimula-be described as acute atrophy and is readily reversible
tion of the Ras-Raf-Erk pathway, which affects musclefollowing exercise. Sarcopenia, an age-related loss of
fiber-type composition but not size, while another path-muscle mass and strength, is considered to be chronic
way, of great significance to the control of muscle size,atrophy and is determined by initial muscle mass and
involves activation of the lipid kinase PI3K. IGF-1 isits subsequent rate of decline. Muscle atrophy resulting
released from muscle in response to increased load/from chronic disease rather than disuse is described as
exercise and plays a role in subsequent hypertrophy ofcachexia and generally arises either from damage to the
muscle through the accumulation of cellular protein.nerves that supply the muscles or from disease of the
IGF-1 achieves this by stimulating translation via a hier-muscle itself. Both causes can be the result of either
archy of activation that begins with PI3K; this leads tounderlying genetic abnormality, such as amyotrophic
the phosphorylation of the serine/threonine kinase Akt1,lateral sclerosis (nerve damage) or muscular dystrophy,
which subsequently results in the regulation of GSK3myotonia congenita (muscle damage); or systemic dis-
andmTORkinases—ultimately leading to increasedpro-ease pathology, such as poliomyelitis (nerve damage)
tein synthesis and muscle hypertrophy (Bodine et al.,inflammatory or metabolic myopathies, diabetes, can-
2001b; Rommel et al., 2001; for review, seeGlass [2003]).cer, renal failure, or pulmonary obstruction (resulting in
Sandri et al. (2004) and Stitt et al. (2004) both focusedmuscle damage) (Marcell, 2003; Glass, 2003).
on this pathway and the possibility that an alternative
The maintenance of skeletal muscle depends upon
target of the IGF-1/PI3K/Akt signaling cascade, the
the balance of dynamic anabolic and catabolic reactions
Forkhead box O (Foxo) family of transcription factors,
to determine the level of muscle protein. Essentially, all may be a possible mediator of atrophy. In two different
atrophic conditions share the commonality of an imbal- models of muscle cultures, a clear atrophy of themuscle
ance in this system, resulting in reduced protein synthe- fibers was induced together with a decrease in IGF-1/
sis and increased protein breakdown/proteolysis, which PI3K/Akt pathway activity. Concurrent with this de-
in turn results in reduced muscle mass and muscle fiber crease was a rapid and robust induction of ubiquitin
size. Given the similarity of the endpoint of diverse ligases, most strongly atrogin-1/MAFbx, suggesting the
atrophic stimuli, onewould expect that commonmecha- mechanism of atrophy was increased protein catabo-
nisms exist via which these stimuli are able to affect lism via ubiquitin-ligase mediated proteolysis. Con-
protein breakdown. Indeed, the process of atrophy is versely, addition of IGF-1 or constitutive activation of
characterized by the activation of distinct pathways, the PI3K/Akt pathway was able to prevent muscle loss
in particular the ATP-dependent ubiquitin-proteasome in these models, apparently by suppressing atrogin-1/
proteolysis pathway. In genetic screens aimed at identi- MAFbx induction. Significantly, in addition to its role as
fyingmarkers ofmuscle atrophy, twogenes in particular, an activator, Akt is also able to functionally inhibit Foxo
atrogin-1/MAFbx and MuRF1, were dramatically upreg- transcription factors by phosphorylation, which results
ulated prior to the onset ofmuscle loss inmultiple exper- in them being sequestered in the cytoplasm. As would
imental models (see Bodine et al. [2001a], Gomes et al. be predicted, the reduction in PI3K/Akt pathway activity
[2001], Stevenson et al. [2003]). Both these genes en- observed in the models of muscle loss resulted in de-
code proteins that are referred to as E3 ubiquitin ligases, creased levels of phosphorylated Foxo in the cytoplasm
and a marked increase of nuclear Foxo protein. When
constitutively active Foxo1 proteins were introduced*Correspondence: mrudnicki@ohri.ca
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Figure 1. IGF1-Akt Signaling and the Balance between Hypertrophy and Atrophy
into myotubes, Stitt et al. (2004) did not observe any While this was an understandable proposal, the ability
to inhibit muscle differentiation or enact a generalizedappreciable change in ubiquitin ligase mRNA levels,
leading them to suggest that active Foxo is not sufficient inflammatory response is a different process from the
precise molecular mechanisms of muscle atrophy offor transcription. However, the introduction of constitu-
tively active Foxo3 by Sandri et al. (2004) was observed which we are now becoming aware. NF-B signaling
can be activated by a number of stimuli; in an inactiveto cause a dramatic increase in the mRNA of atrogin-1/
MAFbx, indicating that this family of transcription fac- state, NF-B is sequestered in the cytoplasm by a family
of inhibitor proteins called the IB. Upon activation oftors may play a direct transcriptional role in the process
of atrophy. Indeed, analysis of the 5 region of the NF-B, these proteins are phosphorylated by IB kinase
(IKK) complexes, resulting in their ubiquitination andatrogin-1/MAFbx gene revealed the presence of a num-
ber of Forkhead binding sites, which, when taken with degradation. This exposes the NF-B nuclear localiza-
tion signal, resulting in translocation to the nucleus,the preceding data, suggests that Foxo binds and acti-
vates the atrogin-1/MAFbxpromoter to affectmuscle at- binding of consensus sequence, and subsequent gene
transcription (Baeuerle and Baltimore, 1996). Recently,rophy.
The significance of these findings is that they demon- Cai et al. (2004) have directly demonstrated an in vivo
role for the transcription factor NF-B in severe musclestrate for the first time a molecular link between the
mediators of hypertrophy and atrophy, showing a direct wasting reminiscent of that observed in clinical cachexia,
via a previously undescribed noncytokine mechanism:anabolic/catabolic balance mechanism involving IGF-1
signaling, whereby the activation of the PI3K/Akt path- the activation of the E3 ubiquitin ligase MuRF1.
The authors demonstrated this by constructing twoway not only promotes muscle growth but also directly
inhibits breakdown via the inhibition of the Foxo family. separate mouse models designed to manipulate NF-B
levels. The NF-B activator IKK (MIKK) and the NF-BIn turn, a reduction in PI3K/Akt pathway activity, which
may result from disease or disuse, releases the Foxo inhibitor IB (MISR) were placed under the control of
a promoter that drives their expression selectively inproteins. The working hypothesis, then, is that Foxo
is free to activate transcriptional targets, in particular skeletal muscle. Although inhibition of NF-Bapparently
failed to reveal a phenotype, activation of NF-B re-atrogin-1/MAFbx, which results in muscle atrophy (Fig-
ure 1). sulted in a specific increase in protein catabolism re-
sulting in muscle atrophy. Significantly, crossing thePreviously, the transcription factor NF-B has been
implicated in the process of muscle wasting as amedia- MISR mouse with the MIKK mouse resulted in a rescue
of the MIKK mouse cachexia phenotype. Furthermore,tor of the cytokine TNF in the inflammatory response,
which in turn triggers both apoptosis of muscle cells and NF-B levels were also assessed in models of nerve
damage and cancer cachexia. Accordingly, levels of NF-specific transcriptional mechanisms that inhibit IGF-1-
induced anabolism (Li et al., 2003; Hunter et al., 2002; B activation and subsequent muscle wasting were ob-
served to rise in both models when using wild-type ani-for review, see Spate and Schulze [2004]). In addition,
the idea that NF-B may be responsible for mediating mals; however, the same experiments performed in
MISR mice yielded a greatly reduced effect, suggestingthe skeletal muscle loss observed in cachexia was first
proposed by Guttridge et al. (2000) in response to their that the effects observed are the result of specific ma-
nipulation of NF-B.observation that TNF-induced activation of NF-B
could suppress the mRNA of the muscle-regulatory fac- Most strikingly, however, the activation of NF-B did
not result in mRNA upregulation of the array of genestor MyoD at the posttranscriptional level.
Minireview
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Figure 2. NF-kB Signaling and Atrophy via
MuRF-1 Induction
typically associated with an NF-B-induced cytokine atrophy caused by disuse. Given the wide range of in-
puts and downstream effects mediated via NF-B sig-response such as that seen in the immune system
(Baeuerle and Baltimore, 1996). Activation of NF-B naling, these alternate pathways may well represent fur-
ther functions of NF-B that directly affect muscleleading to muscle wasting via a noncytokine-related
pathway has been previously proposed in mouse hind- maintenance.
The observation that multiple models of muscle atro-limb disuse and in vitro cell culture models. Prototypical
markers of TNF- activation of NF-Bwere conspicuous phy resulted in the consistent induction of E3 ubiquitin
ligases indicated the great significance of understand-by their absence, and, instead, the effects of NF-B
appeared to be mediated by components of the proteo- ing the molecular mediators that converge upon their
activation. Previously, very little could be stated defini-somal degradation pathway (Hunter et al., 2002; Ladner
et al., 2003). However, the study by Cai et al. (2004) is tively regarding the molecular cascades that transmit
extracellular signals into atrophic responses. The recentthe first report to identify in vivo the link between NF-B
and noncytokine-mediated muscle wasting in cachexic discovery that defined NF-B and IGF-1/PI3K/Akt path-
way activation directly stimulated or attenuated muscleconditions. Cai et al. (2004) observed an increased and
specific induction of MuRF1 in response to increased atrophy via proteolysis, apparently with a degree of ubi-
quitin-ligase specificity, represents a significant step to-NF-B activation, thus indicating a role for NF-B in
cachexia via the activation of proteolysis (Figure 2). ward the goal of countering the debilitating effects of
muscle atrophy. However, the identification of theseWhen the activated NF-B mouse was crossed with
a MuRF1/ knockout mouse, this resulted in a 50% mechanisms is only the initial step, and translating this
information into newmodalities for therapeutic interven-rescue of the atrophic phenotype. The partial rescue of
the phenotype in the compound animals would suggest tion will require considerable effort. For example, stimu-
lation of myotubes with IGF-1 is able to induce myotubethat NF-B is concurrently activating alternative, as yet
undefined pathways. It will be of great importance to hypertrophy (Rommel et al., 2001) and protect against
atrophy via activation of the PI3K-Akt pathway (see Bo-try and further identify these alternative pathways, as
they may represent other levels of atrophy control that dine et al. [2001b] andmodels discussedabove); further-
more, IGF-1 can attenuate the muscle atrophy observedwould be under consideration as therapeutic targets.
For example, a recent report by Hunter and Kandarian in the mdx mouse model of muscular dystrophy when
expressed in a muscle-specific manner (Barton et al.,(2004) has shown that genetic deletion of two further
members of the NF-B family of transcriptional regula- 2002); taken together, these data lend themselves to
the suggestion that delivery of IGF-1 may be a viabletors (Nfkb1 and Bcl3) is able to inhibit skeletal muscle
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Spate, U., and Schulze, P.C. (2004). Curr. Opin. Clin. Nutr. Metab.counter to muscle atrophy. However, systemic delivery
Care 7, 265–269.of IGF-1 would present considerable complications with
Stevenson, E.J., Giresi, P.G., Koncarevic, A., and Kandarian, S.C.regard to its effects upon tissues other than muscle,
(2003). J. Physiol. 551, 33–48.particularly given its ability to stimulate proliferation in
Stitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyva, Y., Kline,particular cell types. While the concept of muscle-tar-
W.O., Gonzalez, M., Yancopoulos, G.D., and Glass, D.J. (2004). Mol.
geted delivery is an attractive one, the absence of a Cell 14, 395–403.
safe and effective delivery method in humans remains
a significant stumbling block. The next logical targets
would be to use pharmacological agents directed
against components of the relevant signaling pathways.
For example, given that acute constitutive activation
of Akt can induce rapid hypertrophy (Lai et al., 2004),
pharmacological mimetics that activate Akt may repre-
sent an attractive and viable strategy. Indeed, this ap-
proach has been used with some success in the mouse
models created by Cai et al. (2004), who used salicylate
to inhibit the NF-B-MuRF1-induced atrophy. However,
as the authors note, the high doses of salicylate required
in the mouse studies are not well tolerated in humans
due to the side effects and its broad range of targets.
Regardless, the identification of precise signaling cas-
cades that direct muscle atrophy has significantly ex-
panded the number of possible targets and strategies to
be explored in clinical interventions aimed at alleviating
muscle atrophy.
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